OBM Genetics

(ISSN 2577-5790)

OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 15.0 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2022  Archive: 2021 2020 2019 2018 2017

Special Issue

Use of Genetic Tests in the Context of Population Screening Strategies

Submission Deadline: July 31, 2022 (Open) Submit Now

Guest Editor

Anne-Marie Laberge, MD, MPH, PhD, Full Clinical Professor

Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and Université de Montréal, Montreal, QC, Canada. 

Website | E-Mail

Research Interests: genetic tests; public health; genetic services in clinical practice; population screening strategies

About the topic:

Traditionally, the use of genetic tests in population screening strategies was limited, because of the complexity and cost of genetic tests made them impractical for high-volume testing and quick turnaround times. Currently available technologies, including next-generation sequencing, are breaking down these barriers.
In newborn and prenatal screening, genetic tests are being added to existing screening algorithms or replacing previously used biochemical tests. In other settings, technological advances are pushing for population screening strategies to be considered for previously unscreened conditions and/or in new populations. For example, there are proponents of population screening for actionable genetic conditions. Some even argue that we should be moving towards genome sequencing of all individuals as a comprehensive screening strategy, as early as in newborns.
With all these possibilities opening up on the horizon, what is the current and future role of genetic tests in population screening strategies? What benefits can be gained from their integration? What limitations and challenges remain to be addressed?

For this special issue, we invite researchers, clinicians, public health specialists and other stakeholders to submit original research articles, reviews, or opinion pieces.